Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q2 2019 Earnings Presentation
8 slides from Angiodynamics's earnings presentation, Jan 4, 2019
Slide 1: AngioDynamics Second Quarter 2019 Earnings Presentation
AngioDynamics Second Quarter 2019 Earnings PresentationJanuary 4, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Second Quarter 2019 Highlights
Second Quarter 2019 Highlights Financial Performance Revenue of $91.5 million, compared to $86.7 million a year ago. Organic revenue was $88.7 million for the second quarter.Gross Margin of 53.7%, up 440 bps year over year. Adjusted EPS of $0.22, compared to $0.17 a year ago.Adjusted EBITDAS of $16.
Slide 4: Second Quarter and Year-to-Date FY 2019 Results
Second Quarter and Year-to-Date FY 2019 Results $ in thousands (except per share data) FY2019 Q2 Results FY2018Q2 Results Change FY2019 YTD Results FY2018 YTD Results Change Revenue- Vascular Interventions and Therapies- Vascular Access- Oncology - United States- International $91,50352,49423,72315,
Slide 5: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 6: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands
Slide 7: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS Amounts in thousands
Slide 8: Growth through Focus Execution Accountability
Growth through Focus Execution Accountability